AU2023240297A1 - Deimmunized antibodies specific for cd3 - Google Patents

Deimmunized antibodies specific for cd3 Download PDF

Info

Publication number
AU2023240297A1
AU2023240297A1 AU2023240297A AU2023240297A AU2023240297A1 AU 2023240297 A1 AU2023240297 A1 AU 2023240297A1 AU 2023240297 A AU2023240297 A AU 2023240297A AU 2023240297 A AU2023240297 A AU 2023240297A AU 2023240297 A1 AU2023240297 A1 AU 2023240297A1
Authority
AU
Australia
Prior art keywords
antibody
seq
antigen
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023240297A
Other languages
English (en)
Inventor
Andreas Bültmann
Markus Moosmeier
Steffen Runz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of AU2023240297A1 publication Critical patent/AU2023240297A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2023240297A 2022-03-22 2023-03-21 Deimmunized antibodies specific for cd3 Pending AU2023240297A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22163663 2022-03-22
EP22163663.2 2022-03-22
PCT/EP2023/057248 WO2023180346A1 (en) 2022-03-22 2023-03-21 Deimmunized antibodies specific for cd3

Publications (1)

Publication Number Publication Date
AU2023240297A1 true AU2023240297A1 (en) 2024-10-03

Family

ID=80930505

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023240297A Pending AU2023240297A1 (en) 2022-03-22 2023-03-21 Deimmunized antibodies specific for cd3

Country Status (9)

Country Link
US (1) US20250206819A1 (cg-RX-API-DMAC7.html)
EP (1) EP4496812A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513714A (cg-RX-API-DMAC7.html)
KR (1) KR20240158351A (cg-RX-API-DMAC7.html)
CN (1) CN118922448A (cg-RX-API-DMAC7.html)
AU (1) AU2023240297A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246381A1 (cg-RX-API-DMAC7.html)
IL (1) IL315591A (cg-RX-API-DMAC7.html)
WO (1) WO2023180346A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025087681A1 (en) 2023-10-26 2025-05-01 Morphosys Ag Bispecific antibodies against cd3 and cd20
KR20260113057A (ko) * 2023-11-14 2026-07-21 리제너론 파아마슈티컬스, 인크. 조작된 중쇄 가변 도메인 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
ATE356385T1 (de) 2002-06-10 2007-03-15 Algonomics N V Verfahren zur vorhersage der bindungsaffinität der mhc-peptid-komplexe
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
EP2640742B1 (en) 2010-11-19 2018-08-15 MorphoSys AG A collection of antibody sequences its use
WO2015070061A1 (en) * 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Anti-wt1/hla bi-specific antibody
IN2014CN03887A (cg-RX-API-DMAC7.html) 2011-10-27 2015-10-16 Genmab As
CN106459201A (zh) * 2014-05-28 2017-02-22 豪夫迈·罗氏有限公司 结合人和食蟹猴CD3ε的抗体
US11472880B2 (en) * 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
CA3121699A1 (en) 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules

Also Published As

Publication number Publication date
JP2025513714A (ja) 2025-04-30
US20250206819A1 (en) 2025-06-26
EP4496812A1 (en) 2025-01-29
CA3246381A1 (en) 2023-09-28
CN118922448A (zh) 2024-11-08
WO2023180346A1 (en) 2023-09-28
KR20240158351A (ko) 2024-11-04
IL315591A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
JP7853939B2 (ja) 二重特異性チェックポイント阻害剤抗体
US11472880B2 (en) Humanized antibodies for CD3
US20210253706A1 (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
JP2021502100A (ja) 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
IL268836B1 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
CN110214148A (zh) 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
JP7080219B2 (ja) 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
US20220106403A1 (en) Heterodimeric antibodies that bind msln and cd3
JP2019529368A5 (cg-RX-API-DMAC7.html)
US20250206819A1 (en) Deimmunized antibodies specific for cd3
TW202342535A (zh) 免疫綴合物及其用途
US20220144956A1 (en) HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
WO2024133890A1 (en) Antibodies targeting cd45
US20250171528A1 (en) Antibodies targeting il3
US20250163182A1 (en) Enpp3 and cd3 binding agents and methods of use thereof
JP2025521496A (ja) Ｃｄ１１７を標的とする抗体
US12304958B2 (en) Antibodies targeting ActRIIA and ActRIIB
TW202241956A (zh) 新穎抗cd24抗體
EA045935B1 (ru) Антитела к cd3 и их применение
HK40014565B (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors